Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Prostatic Neoplasms 2Neoplasm Metastasis 2Breast Neoplasms 2Vaping 1Tobacco Use Disorder 1Stomach Neoplasms 1Ovarian Neoplasms 1Multiple Myeloma 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer 1Granulosa Cell Tumor 1Endometrial Neoplasms 1Abiraterone Acetate 1

Interventions

Oxaliplatin 200Capecitabine 116S 1 (combination) 106Fluorouracil 105Docetaxel 100Cisplatin 88Leucovorin 75Paclitaxel 71Irinotecan 68apatinib 43sintilimab 42Drug Therapy 42Surgical Procedures, Operative 37Hyperthermic Intraperitoneal Chemotherapy 34pembrolizumab 32Radiotherapy 31Trastuzumab 30Gastrectomy 23Nivolumab 22Epirubicin 22Tegafur 21Bevacizumab 21XELOX 20titanium silicide 19camrelizumab 19tislelizumab 17Ramucirumab 17Carboplatin 16Neoadjuvant Therapy 15Endoscopic Mucosal Resection 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Stomach Neoplasms × BID protein, human × Clear all
NCT05216237 2022-04-11

A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) Cancer

Affiliated Hospital of Qinghai University

Phase 2 Unknown
31 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡